355 related articles for article (PubMed ID: 23074173)
21. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
22. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
Jung KH; Noh JH; Kim JK; Eun JW; Bae HJ; Xie HJ; Chang YG; Kim MG; Park H; Lee JY; Nam SW
J Cell Biochem; 2012 Jun; 113(6):2167-77. PubMed ID: 22492270
[TBL] [Abstract][Full Text] [Related]
23. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
24. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
26. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
[TBL] [Abstract][Full Text] [Related]
27. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
28. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Loza-Rosas SA; Vázquez-Salgado AM; Rivero KI; Negrón LJ; Delgado Y; Benjamín-Rivera JA; Vázquez-Maldonado AL; Parks TB; Munet-Colón C; Tinoco AD
Inorg Chem; 2017 Jul; 56(14):7788-7802. PubMed ID: 28644630
[TBL] [Abstract][Full Text] [Related]
29. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
30. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
31. Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
Wang YJ; Jeng JH; Chen RJ; Tseng H; Chen LC; Liang YC; Lin CH; Chen CH; Chu JS; Ho WL; Ho YS
Mol Carcinog; 2002 Aug; 34(4):199-210. PubMed ID: 12203371
[TBL] [Abstract][Full Text] [Related]
32. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
33. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
[TBL] [Abstract][Full Text] [Related]
34. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
35. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
36. [Cyclin D1 regulates lung cancer invasion and metastasis].
Li ZL; Shao SH; Jiao F; Yue Z; Ma Y
Sheng Li Xue Bao; 2012 Feb; 64(1):55-61. PubMed ID: 22348961
[TBL] [Abstract][Full Text] [Related]
37. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
38. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
39. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
40. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
